AI Article Synopsis
- Secondary AA amyloidosis is a rare condition linked to long-term inflammatory disorders, marked by the buildup of fibrils from serum amyloid A (SAA) protein in the body.
- The kidneys are primarily affected, with proteinuria being the first noticeable symptom, and a renal biopsy is typically used for diagnosis.
- Effective treatment involves anti-inflammatory therapies that lower SAA levels to prevent further amyloid buildup, while upcoming treatments may target the removal of existing amyloid deposits.
Article Abstract
Secondary, AA, amyloidosis is a rare systemic complication that can develop in any long-term inflammatory disorder, and is characterized by the extracellular deposition of fibrils derived from serum amyloid A (SAA) protein. SAA is an acute-phase reactant synthetized largely by hepatocytes under the transcriptional regulation of proinflammatory cytokines. The kidney is the major involved organ with proteinuria as first clinical manifestation; renal biopsy is the commonest diagnostic investigation. Targeted anti-inflammatory treatment promotes normalization of circulating SAA levels preventing amyloid deposition and renal damage. Novel therapies aimed at promoting clearance of existing amyloid deposits soon may be an effective treatment approach.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rdc.2018.06.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!